Worry and Anxiety Questionnaire (WAQ)

1. Abstract

The Worry and Anxiety Questionnaire (WAQ; French: Questionnaire d’Inquiétude et d’Anxiété, QIA) is a standardized self-report psychometric instrument developed by Michel J. Dugas and colleagues to assess the defining diagnostic features of Generalized Anxiety Disorder (GAD) as operationalized in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-5). GAD is primarily characterized by chronic, excessive, and uncontrollable worry across multiple domains of everyday functioning, accompanied by distinct somatic and cognitive symptoms such as muscle tension, restlessness, mental fatigue, impaired concentration, irritability, and disturbed sleep. The WAQ was specifically designed to bridge the methodological gap between lengthy, clinician-administered structured diagnostic interviews—such as the Structured Clinical Interview for DSM (SCID) and the Anxiety and Related Disorders Interview Schedule (ADIS)—and generalized dimensional trait anxiety scales, such as the Penn State Worry Questionnaire (PSWQ).

Comprising 11 operationalized items across distinct thematic sections (capturing worry themes, perceived excessiveness, chronicity over a 6-month threshold, uncontrollability, six somatic/cognitive symptoms, and functional impairment), the WAQ can be scored both as a continuous severity metric and as a categorical diagnostic screening tool. Subsequent psychometric revisions by Amélie Doucet (WAQ-II, 2008) expanded response scales to 9-point Likert-type arrays (0–8) to heighten measurement precision and reduce ceiling or floor attenuation. Psychometric investigations in non-clinical undergraduate cohorts, community populations, and clinical samples have demonstrated solid internal consistency (Cronbach’s alpha coefficients routinely ranging between α = .80 and .91), commendable test-retest reliability across 2- to 4-week latency periods (r = .75–.86), and strong convergent validity with established measures of trait anxiety, worry frequency, and intolerance of uncertainty. Receiver operating characteristic (ROC) analyses confirm superior diagnostic efficiency, with sensitivity and specificity indices typically exceeding 80% when benchmarked against gold-standard semi-structured psychiatric interviews.

2. Keywords

Worry and Anxiety Questionnaire, WAQ, Generalized Anxiety Disorder, GAD screening, excessive worry, cognitive uncontrollability, intolerance of uncertainty, DSM-5 diagnostic criteria, somatic anxiety, psychometrics, clinical assessment, test-retest reliability, construct validity, diagnostic efficiency

3. Authors

The Worry and Anxiety Questionnaire was primarily formulated, developed, and psychometrically validated by clinical psychologists and psychometric researchers associated with the Anxiety Disorders Laboratory at Université Laval (Québec, Canada) and Concordia University (Montréal, Canada):

• Michel J. Dugas, Ph.D.: Professor of Psychology, Department of Psychology, Concordia University and Université du Québec en Outaouais; international authority on cognitive-behavioral conceptualizations of Generalized Anxiety Disorder and the Intolerance of Uncertainty Model.
• Mark H. Freeston, Ph.D.: Professor of Clinical Psychology, Institute of Neuroscience, Newcastle University (UK), formerly affiliated with Université Laval and the Centre de Recherche Université Laval Robert-Giffard; expert in obsessive-compulsive phenomena and the cognitive architecture of anxiety.
• Robert Ladouceur, Ph.D.: Emeritus Professor of Psychology, École de Psychologie, Université Laval; pioneering researcher in cognitive-behavioral therapy (CBT) for GAD, pathological gambling, and anxiety maintenance mechanisms.
• Martin D. Provencher, Ph.D.: Professor of Clinical Psychology, École de Psychologie, Université Laval; specialist in empirical clinical trials and evidence-based interventions for mood and anxiety disorders.
• Stéphane Lachance, Ph.D.: Clinical psychologist and researcher whose investigations focused on the psychometric differentiation of pathological versus non-pathological worry.
• Patrick Gosselin, Ph.D.: Professor, Département de Psychologie, Université de Sherbrooke; leading investigator on worry schemas, cognitive avoidance, and developmental factors in anxiety psychopathology.
• Amélie Doucet, Ph.D.: Clinical psychologist and researcher who spearheaded the subsequent structural revision, parameter optimization, and metric extension resulting in the Worry and Anxiety Questionnaire II (WAQ-II, 2008).

4. Purpose

The primary clinical and psychometric purpose of the Worry and Anxiety Questionnaire is to provide an efficient, theoretically anchored, and empirically validated assessment tool that directly captures all symptomatic criteria required for the classification of Generalized Anxiety Disorder. Prior to the development of the WAQ, researchers and clinical practitioners encountered severe practical trade-offs when evaluating worry and GAD:

• Limitations of Trait Worry Scales: While dimensional questionnaires such as the Penn State Worry Questionnaire (PSWQ) measure the general trait propensity to worry, its frequency, and subjective uncontrollability with high reliability, they omit critical DSM diagnostic criteria. Specifically, the PSWQ does not evaluate somatic anxiety symptoms (e.g., muscle tension, motor restlessness), chronicity parameters (such as the DSM criterion of persisting for at least 6 months on more days than not), or explicit functional impairment across vocational, academic, and interpersonal domains.
• Logistical Burden of Structured Clinical Interviews: Conversely, gold-standard clinician-administered instruments, such as the Structured Clinical Interview for DSM-IV/DSM-5 Axis I Disorders (SCID) or the Anxiety and Related Disorders Interview Schedule (ADIS), require specialized clinical training, consume between 45 and 90 minutes per administration, and introduce high institutional costs that make wide-scale epidemiological screenings or rapid session-by-session clinical monitoring unfeasible.

The WAQ addresses these challenges by offering a structured, 11-item self-report questionnaire that systematically operationalizes DSM-IV and DSM-5 criteria into accessible, quantifiable questions. In research applications, the instrument serves multiple functions: as a continuous measure of GAD symptom severity; as a rigorous categorical diagnostic screen to assign participants into probable GAD versus non-anxious control groups; and as a sensitive outcome metric to track treatment response during randomized controlled trials of cognitive-behavioral therapy or pharmacotherapy.

In clinical practice, the WAQ functions as an intake triage screen, identifying patients who warrant a comprehensive diagnostic evaluation for GAD. Because it itemizes individual somatic complaints (e.g., sleep disturbance, muscle tension, mental exhaustion) and assesses life interference, clinicians can use the profile of WAQ responses to personalize intervention targets. For instance, high ratings on somatic items suggest the utility of somatic regulation techniques (e.g., progressive muscle relaxation), whereas disproportionate scores on uncontrollability and excessiveness indicate the need for cognitive restructuring, problem-solving training, or uncertainty-tolerance exposure protocols.

5. Psychological Construct

The psychological construct evaluated by the WAQ is the multifaceted syndromal architecture of Generalized Anxiety Disorder, with pathological worry positioned as its primary cognitive manifestation. Rather than treating anxiety as a unitary, undifferentiated emotional state, the WAQ unpacks the construct into distinct cognitive, temporal, physiological, and functional components:

5.1. The Content and Multiplicity of Worry Themes (Criterion A1)

The instrument operationalizes worry as an apprehensive cognitive process consisting of verbal-linguistic thoughts concerning potential negative future events. By prompting respondents to list the primary topics that preoccupy their thinking (e.g., family, health, finances, vocational competence, minor daily hassles), the WAQ assesses the criterion of worry multiplicity. In non-pathological individuals, worry is typically confined to a single, circumscribed, and immediate crisis. In contrast, in pathological GAD, worry spreads across multiple life domains, reflecting pervasive cognitive threat appraisal.

5.2. Subjective Excessiveness and Disproportionality (Criterion A2)

A cardinal diagnostic feature of GAD is that the intensity, duration, or frequency of the worry is out of proportion to the objective likelihood or actual impact of the feared event. The WAQ explicitly evaluates whether respondents perceive their cognitive concerns as exaggerated, catastrophic, or unwarranted relative to reality. This subjective appraisal distinguishes realistic vigilance from maladaptive cognitive distortion.

5.3. Chronicity and Temporal Stability (Criterion A3)

Transient periods of elevated worry are normative responses to acute psychosocial stress. The GAD construct, however, requires chronicity. The WAQ operationalizes this dimension by evaluating the temporal frequency of worry over the preceding six months, determining whether excessive thoughts have been experienced on “more days than not” (i.e., at least 50% of the days over a half-year interval).

5.4. Perceived Lack of Cognitive Control (Criterion B)

A key distinguishing feature between non-pathological worriers and clinical individuals is the perceived uncontrollability of the worry chain. Patients with GAD perceive that once a catastrophic scenario enters consciousness, they lack the cognitive control or behavioral strategies necessary to terminate the ideational sequence. The WAQ quantifies this difficulty, measuring the degree to which worry functions as an intrusive, autonomous process that resists conscious suppression or redirection.

5.5. Somatosensory and Cognitive Manifestations (Criterion C)

Unlike panic disorder (which features intense, autonomic sympathetic surges such as tachycardia, hyperventilation, and acute dizziness), GAD is characterized by persistent central nervous system hyperarousal and chronic motor tension. The WAQ assesses six diagnostic somatic and cognitive signs:

• Restlessness or feeling keyed up/on edge: Motoric agitation and heightened psychomotor readiness.
• Easy fatigability: Rapid depletion of physiological and mental resources resulting from chronic baseline vigilance.
• Concentration difficulties or mind going blank: Cognitive interference caused by working memory resources being monopolized by threat-related verbal worry chains.
• Irritability: Lowered affective tolerance for frustration and environmental stressors.
• Muscle tension: Chronic musculoskeletal strain, particularly localized in the facial, nuchal, shoulder, and upper back musculature.
• Sleep disturbance: Difficulties initiating or maintaining sleep, or experiencing unrestorative, fitful sleep due to cognitive hyperarousal at bedtime.

5.6. Functional Impairment and Subjective Distress (Criterion E/D)

A cognitive or somatic symptom becomes clinically significant when it leads to functional impairment. The WAQ assesses the extent to which worry and physiological hyperarousal interfere with vocational productivity, academic pursuits, social relationships, and familial responsibilities, alongside the degree of personal distress experienced.

6. Theoretical Framework

The architectural foundation of the WAQ is situated within the Intolerance of Uncertainty (IU) Model of Generalized Anxiety Disorder, formulated by Michel J. Dugas, Robert Ladouceur, and Mark H. Freeston at Université Laval. This cognitive model posits that intolerance of uncertainty acts as the core vulnerability factor that initiates, intensifies, and perpetuates chronic worry.

6.1. The Intolerance of Uncertainty Core

According to this model, individuals with elevated IU perceive uncertain, ambiguous, or unpredictable situations as inherently unfair, threatening, intolerable, and debilitating. When faced with ambiguous future possibilities, high-IU individuals experience cognitive distress and engage in catastrophic cognitive forecasting (“What if…?”). Worry is deployed as an ineffective, maladaptive mental coping mechanism intended to mentally anticipate all possible negative outcomes, reduce surprise, and regain subjective control. However, because absolute certainty regarding the future is impossible, the worry process becomes self-perpetuating, leading to elevated chronic arousal.

6.2. The Interacting Quadrant of the Cognitive Model

The theoretical framework driving the WAQ includes four interconnected components that interact with intolerance of uncertainty:

1. Intolerance of Uncertainty: The dispositional cognitive filter that interprets ambiguous situations as unacceptable and distressing.
2. Positive Beliefs About Worry: Metacognitive convictions that worrying is functionally advantageous (e.g., “Worrying helps me find solutions,” “Worrying protects me from disappointment,” “Worrying demonstrates that I am a caring person”). These metacognitions reinforce early engagement in worry episodes.
3. Negative Problem Orientation: A dysfunctional cognitive set regarding one’s problem-solving capacity, characterized by viewing problems as immediate threats to well-being, doubting personal competence, and feeling easily overwhelmed. This leads to experiential avoidance or impulsive, incomplete solutions, perpetuating unresolved difficulties.
4. Cognitive Avoidance: Drawing from Borkovec’s avoidance theory of worry, verbal-linguistic worry suppresses deeper, more distressing visual imagery and prevents full autonomic emotional processing. Because verbal worry dampens immediate visceral arousal, it is negatively reinforced; however, it precludes emotional habituation and cognitive reappraisal, locking the patient into a cycle of chronic vigilance.

The WAQ is designed to capture the clinical output of this pathogenic cognitive-affective engine: the relentless generation of threat scenarios (excessiveness/uncontrollability), the physical strain of constant vigilance (somatic symptoms), and the resulting vocational and social breakdown (functional impairment).

7. Validity

The psychometric validity of the Worry and Anxiety Questionnaire has been confirmed across clinical, university, and community samples.

7.1. Criterion-Related and Diagnostic Validity

The primary validation study by Dugas et al. (2001) evaluated the diagnostic accuracy of the WAQ against the Structured Clinical Interview for DSM-IV (SCID). In a sample of outpatients seeking treatment at specialized anxiety clinics alongside non-clinical controls, the WAQ demonstrated strong diagnostic concordance:

• Sensitivity: Ranged between 83.3% and 86.2%, indicating that the vast majority of individuals meeting SCID criteria for GAD were successfully flagged by the WAQ algorithm.
• Specificity: Ranged between 84.4% and 92.7%, reflecting a minimal rate of false-positive misclassifications among non-GAD controls and individuals with other distinct anxiety disorders (such as Social Anxiety Disorder or Panic Disorder).
• Diagnostic Agreement: Cohen’s kappa coefficients (κ) with clinical interview classifications consistently exceeded .70, demonstrating strong categorical agreement beyond chance.

7.2. Convergent Validity

The WAQ demonstrates strong, statistically significant convergent correlations with established measures of worry and affective distress:

• Penn State Worry Questionnaire (PSWQ): Continuous WAQ scores correlate strongly with the PSWQ (typically between r = .65 and r = .78, p < .001), confirming that both instruments capture the core construct of pathological worry.
• State-Trait Anxiety Inventory (STAI-Trait): Correlations with trait anxiety range between r = .60 and r = .72.
• Intolerance of Uncertainty Scale (IUS): Strong associations are observed with the IUS (r = .55 to r = .68), confirming the theoretical link between uncertainty intolerance and GAD symptomatology.
• Beck Depression Inventory (BDI/BDI-II): Moderate correlations are found with depressive symptom measures (r = .45 to r = .58), reflecting the established clinical comorbidity between generalized anxiety and dysphoria while maintaining adequate discriminant divergence.

7.3. Discriminant and Incremental Validity

To verify discriminant validity, researchers evaluated WAQ scores in clinical cohorts with panic disorder, obsessive-compulsive disorder (OCD), and major depressive disorder without secondary GAD. While these clinical control groups showed elevated WAQ scores compared to non-clinical populations, individuals with primary GAD scored significantly higher across the worry excessiveness, uncontrollability, and somatic symptom clusters. Furthermore, ROC curve analyses by Dugas and colleagues confirmed that the area under the curve (AUC) consistently surpasses .88, demonstrating that the WAQ provides incremental diagnostic utility beyond general negative affectivity scales.

8. Reliability

Psychometric evaluations have demonstrated that the WAQ possess robust reliability across both non-clinical and psychiatric populations.

8.1. Internal Consistency

The internal consistency of the WAQ’s continuous dimensions (specifically the 6-item somatic/cognitive symptom cluster and the composite total severity score) has been evaluated using Cronbach’s alpha and McDonald’s omega:

• Somatic/Cognitive Symptom Cluster (Items 5a–5f in original WAQ; 6a–6f in WAQ-II): Across student, community, and clinical cohorts, Cronbach’s alpha consistently falls between α = .80 and α = .88.
• Total Score / Full Dimension: When continuous items (excessiveness, uncontrollability, somatic symptoms, interference, and distress) are summed, composite reliability ranges from α = .83 to α = .91. Item-total correlations for individual somatic symptoms consistently exceed r = .48, with muscle tension and feeling keyed up/on edge demonstrating the highest item-scale correlations (often r > .65).

8.2. Test-Retest Reliability and Temporal Stability

Because GAD is conceptualized as a chronic, enduring clinical condition rather than a fluctuating emotional state, temporal stability is critical. Studies assessing test-retest reliability across intervals of two to four weeks in non-treated samples report stability coefficients ranging between r = .75 and r = .86. In categorical analyses, diagnostic classification stability remains robust, with test-retest kappa coefficients indicating consistent diagnostic assignment over a 1-month window (κ = .68–.77). Parallel stability figures were replicated during the psychometric validation of the WAQ-II by Doucet (2008), where expanded 0–8 response anchors further stabilized item variance across repeated measurements.

9. Factor Analysis

Both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have been conducted on the WAQ and WAQ-II items to elucidate the underlying latent structure of the instrument.

9.1. Factor Structure Findings

Psychometric investigations indicate that the WAQ is best represented by a correlated two-factor model, although a hierarchical (bifactor) model with a strong general GAD severity factor also demonstrates acceptable fit:

• Factor 1: Cognitive Worry and Impairment: Encompasses items measuring worry excessiveness, temporal chronicity, perceived uncontrollability, and functional interference/distress. Standardized factor loadings for this dimension are uniformly high, typically loading between λ = .68 and λ = .85.
• Factor 2: Somatosensory Hyperarousal (Somatic/Cognitive Manifestations): Encompasses the six specific DSM physiological and cognitive symptoms: restlessness, fatigue, concentration difficulties, irritability, muscle tension, and sleep disturbance. Factor loadings for these symptom indicators range from λ = .55 to λ = .81.

9.2. Confirmatory Factor Analytic Fit Indices

In structural modeling studies examining the latent dimensional validity of the continuous items, the correlated two-factor structure yielded good fit indices:

• Comparative Fit Index (CFI): .94 to .97, exceeding standard adequacy thresholds.
• Tucker-Lewis Index (TLI): .92 to .96.
• Root Mean Square Error of Approximation (RMSEA): .048 to .064 (90% confidence intervals routinely spanning .035 to .075), indicating acceptable to close approximate fit.
• Standardized Root Mean Square Residual (SRMR): .038 to .051.

These factor analytic results support the dual-component model of GAD, demonstrating that while excessive cognitive worry and somatic hyperarousal represent distinct symptom clusters, they are bound by a common, overarching GAD psychopathological core.

10. Instrument / Measurement Tool

The Worry and Anxiety Questionnaire exists in two primary iterations: the original 11-item WAQ (Dugas et al., 2001) and the revised WAQ-II (Doucet, 2008). Below are the structural, scoring, and diagnostic administration characteristics:

• Instrument Type: Self-report screening and dimensional assessment inventory.
• Administration Time: Approximately 5 to 10 minutes.
• Target Population: Adolescents and adults (ages 16 and older).
• Item Configuration (Original WAQ):
  • Item 1: Open-ended qualitative listing of frequent worry themes (identifies worry multiplicity across everyday domains: health, finances, family, work, etc.).
  • Item 2: Assessment of perceived excessiveness/exaggeration (rated on a 1 to 5 Likert-type scale).
  • Item 3: Assessment of chronicity/frequency over the past 6 months (1 = Never, 3 = 1 day out of 2, 5 = Everyday).
  • Item 4: Difficulty controlling worries / uncontrollability (rated 1 to 5).
  • Item 5 (a–f): Severity of 6 DSM somatic/cognitive symptoms over the past 6 months: restlessness, easy fatigability, concentration problems, irritability, muscle tension, and sleep disturbance (each rated 1 to 5).
  • Item 6: Life interference across vocational, social, and familial spheres (rated 1 to 5).
• Item Configuration (Revised WAQ-II, Doucet 2008):
  • Definition Prompt: Explicit cognitive framing provided to respondents: “Worry is a chain of upsetting thoughts about something bad that could happen to you or to others.”
  • Item 1: Qualitative listing of worry topics (options a through h).
  • Items 2 to 8: Standardized on an expanded 9-point Likert scale (anchors: 0 = Not at all, 2 = Slightly, 4 = Moderately, 6 = Very Much, 8 = Extremely; or frequency: 0 = Never, 2 = Some days, 4 = 50% of days, 6 = Most days, 8 = Everyday).
• Diagnostic Algorithm / Scoring Rules (Categorical GAD Determination – Original WAQ):

  To screen positive for probable Generalized Anxiety Disorder according to DSM-IV/DSM-5 diagnostic criteria, a respondent must fulfill all of the following operational benchmarks:

  1. Criterion A (Excessive Worry): Item 2 scored ≥ 4 (moderately to totally excessive) AND Item 3 scored ≥ 3 (present at least 1 day out of 2 / 50% of days over the preceding 6 months).
  2. Criterion B (Uncontrollability): Item 4 scored ≥ 4 (moderate to extreme difficulty controlling worry).
  3. Criterion C (Somatic/Cognitive Signs): At least 3 out of the 6 somatic items (5a through 5f) must be endorsed at a moderate-to-severe threshold (each scored ≥ 3 or ≥ 4, depending on the conservative clinical cutoff applied).
  4. Criterion E (Functional Interference): Item 6 scored ≥ 3 or ≥ 4 (moderately to very severely interfering with vocational, social, or family life).
• Continuous Dimensional Scoring:

  A continuous severity index can be calculated by summing all Likert-scaled items. On the original WAQ, summing items 2, 3, 4, 5a–f, and 6 yields a continuous severity score ranging from 10 to 50. On the WAQ-II, continuous summation yields scores ranging from 0 to 88, providing an index of total GAD symptom load useful for tracking clinical progress over time.

11. Permissions & Fee and Test Year

• Original Publication Year: 2001 (initial empirical validation published in the Journal de Thérapie Comportementale et Cognitive); preliminary iterations utilized in clinical trials since 1995–1998.
• Revised Version Year (WAQ-II): 2008 (developed by Amélie Doucet, Université Laval).
• Copyright & Ownership: Intellectual property resides with the original authors (Michel J. Dugas, Ph.D., Mark H. Freeston, Ph.D., Robert Ladouceur, Ph.D., and Amélie Doucet, Ph.D.).
• Licensing and Clinical/Research Accessibility: The Worry and Anxiety Questionnaire is considered an open-access academic instrument. It is made freely available for non-commercial academic research, empirical investigations, and individual clinical assessments without royalty or licensing fees, provided proper bibliographic attribution is maintained. Commercial digital platforms, test publishers, or proprietary applications must secure explicit written permission from the primary authors.

12. References

• Doucet, A. (2008). Le trouble d’anxiété généralisée: Étude de la structure factorielle et validation psychométrique d’une version révisée du Questionnaire d’Inquiétude et d’Anxiété (QIA-II) (Master’s thesis, Université Laval). Collection d’archives de Bibliothèque et Archives Canada. https://www.collectionscanada.gc.ca/obj/s4/f2/dsk3/ftp04/MQ64017.pdf
• Dugas, M. J., Freeston, M. H., Doucet, C., Lachance, S., & Ladouceur, R. (1995). Structured versus free-recall measures: Effects on report of worry themes. Personality and Individual Differences, 18(3), 355–362. https://doi.org/10.1016/0191-8869(94)00157-M
• Dugas, M. J., Freeston, M. H., & Ladouceur, R. (1997). Intolerance of uncertainty and problem orientation in worry. Cognitive Therapy and Research, 21(6), 593–606. https://doi.org/10.1023/A:1021890322153
• Dugas, M. J., Freeston, M. H., Provencher, M. D., Lachance, S., Ladouceur, R., & Gosselin, P. (2001). The Worry and Anxiety Questionnaire: Validation in nonclinical and clinical samples. Journal de Thérapie Comportementale et Cognitive, 11(1), 31–36. https://doi.org/10.1016/S1155-1704(01)72365-8
• Dugas, M. J., Gagnon, F., Ladouceur, R., & Freeston, M. H. (1998). Generalized anxiety disorder: A preliminary test of a conceptual model. Behaviour Research and Therapy, 36(2), 215–226. https://doi.org/10.1016/S0005-7967(97)10017-X
• Dugas, M. J., Gosselin, P., & Ladouceur, R. (2001). Intolerance of uncertainty and worry: Investigating narrow specificity in a nonclinical sample. Cognitive Therapy and Research, 25(5), 551–558. https://doi.org/10.1023/A:1005553414688
• Ladouceur, R., Dugas, M. J., Freeston, M. H., Léger, E., Gagnon, F., & Thibodeau, N. (2000). Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: Evaluation in a controlled clinical trial. Journal of Consulting and Clinical Psychology, 68(6), 957–964. https://doi.org/10.1037/0022-006X.68.6.957

13. Items of the Scale (Questionnaire)